Search Results

LIXTE Biotechnology Holdings, Inc., a clinical stage pharmaceutical company, announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metastatic colon cancer.

About a year after cutting staff by 29%, Sana Biotechnology will trim its workforce as it increases investment in its type 1 diabetes program and looks to extend its cash runway.

LIXTE Biotechnology Holdings, Inc., a clinical stage pharmaceutical company, announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metastatic colon cancer.

Renal Research Institute, a global leader in dialysis and nephrology research and a subsidiary of Fresenius Medical Care AG, announced together with the Karolinska Institutet a joint symposium, “Prevention of CKD progression: the impact of new therapeutics.” The Karolinska Institutet is one of the world’s leading medical universities.

Immutep Limited ACN 009 237 889 is pleased to announce the successful completion of its institutional placement and the institutional component of its 1 for 16 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.

LIXTE Biotechnology Holdings, Inc. announced it is co-sponsoring an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s Dana Farber Cancer Institute on May 9 and 10, 2024 in Boston, Massachusetts.

Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, announced it has successfully completed 11 installs of its eProtein Discovery™ system, including at leading academic institutes.

Siren Biotechnology announced that the California Institute for Regenerative Medicine has awarded the company a $4M translational research grant to support the development of novel AAV immuno-gene therapies for cancer.